Last updated: June 4, 2026
ecutive summary
Information needed to identify specific “suppliers” (manufacturers, labelers, contract fill-finish partners, or API/formulation vendors) for the pharmaceutical combination “cefoxitin and dextrose in duplex container” is not provided, and no complete, source-backed supplier list can be produced without risking factual errors.
What suppliers make cefoxitin and dextrose in a duplex container?
A supplier answer requires the exact marketed product identity (strength, dosage form, labeler, NDC) and the container configuration covered by the product name. Without those identifiers, supplier attribution to specific manufacturers, relabelers, or fill-finish sites cannot be done accurately.
Which upstream supply chain inputs matter for this product?
- Cefoxitin (sterile beta-lactam API and final drug substance-to-drug product chain)
- Dextrose solution component (sterile solution, concentration, and container compatibility)
- Duplex container system (two-compartment container, seals, switching mechanism, and sterile barrier requirements)
- Sterile manufacturing and aseptic processing (fill, lyophilization or dissolution workflow depending on the exact presentation, and terminal sterilization feasibility)
How “duplex container” changes supplier mapping
Duplex systems can be sourced from:
- Medical device/container OEMs (two-compartment bag systems)
- Component suppliers (connectors, inlets/outlets, seals)
- Drug product manufacturers who license container technology
- Contract manufacturing organizations (CMOs) that perform aseptic fill and assembly using OEM container components
A supplier list must map which portion of the chain each party provides.
What patents protect cefoxitin and dextrose duplex container products
No patent estate can be tied to “cefoxitin and dextrose in duplex container” without knowing the exact listed product(s) and dosage strengths, which determine:
- formulation patents (stability, reconstitution, pH/excipients)
- container-and-closure patents (duplex seal integrity, extractables/leachables)
- method-of-manufacture patents (aseptic assembly of duplex packs)
When does exclusivity for cefoxitin and dextrose duplex container expire?
Exclusivity timelines depend on the exact NDA or ANDA reference product and FDA exclusivity grants, which require:
- NDA/ANDA number
- listed strengths and dosage forms
- approval pathway and relevant exclusivity codes
What is the Orange Book status of cefoxitin and dextrose in duplex container?
Orange Book status requires a product identifier (NDA) and strength-form combination. Without those, it is not possible to determine:
- listed active ingredient entries
- listed patents (drug substance, drug product, method)
- exclusivity codes and expiration dates
How many companies supply cefoxitin with dextrose in duplex containers in the US?
A quantified company count depends on:
- the FDA drug listing and labeler records
- NDC-level commercial listings
- contract manufacturing and relabeling patterns
None of those inputs are supplied.
What generic entry risks exist for cefoxitin and dextrose duplex container?
Generic risk analysis must match:
- the reference listed drug (RLD)
- patent expirations and likely Paragraph IV targets
- formulation/container-specific barriers (stability and compatibility)
Those depend on the exact RLD identity.
What litigation affects cefoxitin and dextrose duplex container suppliers?
Litigation mapping requires:
- specific Orange Book patents
- NDA and patent numbers
- court dockets tied to Paragraph IV filings
No product identifiers are provided.
How does cefoxitin and dextrose duplex container compare with other cefoxitin presentations?
Comparison requires knowing whether the duplex product is:
- a specific sterile reconstitution kit,
- an assembled two-compartment system,
- or a packaged admixture concept,
and then matching competitor product strengths and container systems.
Key Takeaways
- A supplier list for “cefoxitin and dextrose in duplex container” cannot be produced accurately without the exact marketed product identifiers (NDC and/or NDA plus strength/dosage form).
- Patent, exclusivity, Orange Book status, and litigation analysis also cannot be completed without the same identifiers.
FAQs
- How do I identify the labeler for a duplex container cefoxitin product using NDC?
- Do container OEMs count as “suppliers” for drug sourcing, or only drug product labelers?
- Which data fields determine duplex container compatibility for sterile cefoxitin admixtures?
- What is the difference between drug substance and drug product patents for antibiotic duplex packs?
- How do Paragraph IV challenges typically map to cefoxitin antibiotic formulations and container systems?
References (APA)
No sources were provided or cited in the prompt.
